GSK response to SFO Statement

RNS Number : 8883Q

GlaxoSmithKline PLC

22 February 2019

 

Issued: 22 February 2019, London UK - LSE Announcement

GSK response to SFO Statement

In reference to the announcement issued by the Serious Fraud Office ("SFO") today, GlaxoSmithKline plc (LSE/NYSE: GSK) is pleased that the SFO have closed their investigation and concluded that no further action is required.

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.

GSK enquiries:
UK Media enquiries:	Simon Steel	[phone]	(London)
	Tim Foley	[phone]	(London)
Analyst/Investor enquiries:	Sarah Elton-Farr	[phone]	(London)
	Jeff McLaughlin	[phone]	(Philadelphia)

Cautionary statements regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2017.
Registered in England & Wales: No. 3888792
Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS

 

END

 

 

RSPEAFAAAFKNEFF